home / stock / rcus / rcus quote
Last: | $14.785 |
---|---|
Change Percent: | -0.37% |
Open: | $14.74 |
Close: | $14.84 |
High: | $14.91 |
Low: | $14.51 |
Volume: | 189,140 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$14.785 | $14.74 | $14.84 | $14.91 | $14.51 | 189,140 | 04-18-2024 |
$14.84 | $15.95 | $14.84 | $16.04 | $14.79 | 791,244 | 04-17-2024 |
$15.87 | $16.32 | $15.87 | $16.62 | $15.85 | 329,031 | 04-16-2024 |
$16.29 | $16.56 | $16.29 | $16.66 | $16.03 | 433,335 | 04-15-2024 |
$16.58 | $17.21 | $16.58 | $17.4994 | $16.165 | 492,167 | 04-12-2024 |
$17.29 | $16.92 | $17.29 | $17.37 | $16.66 | 378,251 | 04-11-2024 |
$16.73 | $16.91 | $16.73 | $17.12 | $16.501 | 507,753 | 04-10-2024 |
$17.45 | $17.04 | $17.45 | $17.64 | $16.83 | 495,332 | 04-09-2024 |
$16.97 | $17.41 | $16.97 | $17.56 | $16.69 | 285,883 | 04-08-2024 |
$17.34 | $17.08 | $17.34 | $17.35 | $16.61 | 496,895 | 04-05-2024 |
$17.27 | $17.8 | $17.27 | $18.06 | $17.21 | 580,123 | 04-04-2024 |
$17.69 | $17.62 | $17.69 | $17.84 | $17 | 564,784 | 04-03-2024 |
$17.72 | $18.03 | $17.72 | $18.265 | $17.57 | 891,425 | 04-02-2024 |
$18.48 | $18.78 | $18.48 | $18.85 | $18.22 | 514,782 | 04-01-2024 |
$18.88 | $18.3 | $18.88 | $19.11 | $18.18 | 744,391 | 03-29-2024 |
$18.88 | $18.3 | $18.88 | $19.11 | $18.18 | 744,391 | 03-28-2024 |
$18.21 | $16.9 | $18.21 | $18.54 | $16.6422 | 1,005,729 | 03-27-2024 |
$16.65 | $16.66 | $16.65 | $16.745 | $16.31 | 917,496 | 03-26-2024 |
$16.47 | $16.47 | $16.47 | $16.69 | $16.1 | 578,538 | 03-25-2024 |
$16.43 | $17.15 | $16.43 | $17.22 | $16.37 | 574,806 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
2024-04-14 06:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Lee...
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical needs and largest market opportunities Pharmacokinetic (PK), pharmacodynamic (PD), safety and...